ReviewToxins2017
Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa.
Review in Toxins, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Human Metapneumovirus G Protein Immunogenicity and Safety Explored via Carrier Protein Fusion.Tropical medicine and infectious disease · 2026Article
- Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.Pharmaceutics · 2025Article
- Designing a conjugate vaccine targetingHeliyon · 2024Article
- The diverse landscape of AB5-type toxins.Engineering microbiology · 2023Review
- An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.PloS one · 2023Article
- Recombinant BCG to Enhance Its Immunomodulatory Activities.Vaccines · 2022Review
- Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis.The Journal of pharmacology and experimental therapeutics · 2022Article
- Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing.Pharmaceutics · 2021Article
- Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.Toxins · 2021Review
- Evaluation of the Efficacy of a Cholera-Toxin-BasedVaccines · 2020Article
- A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repairFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Article
- Consuming cholera toxin counteracts age-associated obesity.Oncotarget · 2019Article
- Sensitive and rapid detection of cholera toxin subunit B using magnetic frequency mixing detection.PloS one · 2019Article
- A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform.Journal of bacteriology · 2018Article
- Toxins in Drug Discovery and Pharmacology.Toxins · 2018Article
- Protection AgainstFrontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera toxin B subunit (CTB) is a mucosal immunomodulatory protein that induces robust mucosal and systemic antibody responses. This well-known biological activity has been exploited in cholera prevention (as a component of Dukoral
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.